The thesis
SilentDip rests on a tidy, well-documented asymmetry: a sharp drop without negative headlines tends to be noise that reverts to the mean, while the same drop carrying genuine bad news keeps drifting lower. The strategy therefore demands two things at once — oversold technicals and the absence of salient negative sentiment — before it buys, then exits as the name mean-reverts to its SMA20 or RSI normalises. It leans on Clinch, He, Landsman & Li (SSRN, Nov 2025), which extends Chan's classic 2003 work on price reaction to news versus no-news. That is a respectable lineage, and the design follows it faithfully across a conservative 24-name large-cap universe (AAPL, MSFT, JPM, XOM, CAT and similar).
Recent activity
The live book is doing something the thesis implies but which still reads as striking: almost nothing. The last six scheduled runs (4–11 Nov) each closed 0 executed, 0 rejected. The only recent fill is a single trade — 2 shares of CAT at $622.54 on 30 Oct. Total account value has drifted between $9,858 and $9,949 over the week, with $8,740 of that parked in cash. So the strategy is currently roughly flat and overwhelmingly uninvested.
This is a feature, not a bug — a selective reversion system should sit out when no clean dip appears. But it is worth naming the cost: idle cash is a real drag, and a strategy that trades this rarely will test an operator's patience long before it tests their risk limits.
Backtest and validation
The historical record is strong. Over 1,279 days the backtest returned 52.62% (final equity $15,262, CAGR 8.69%), with a 70.55% win rate across 294 trades and a contained 10.38% max drawdown. Sharpe of 1.03 is solid rather than spectacular — this is a steady grinder, not a rocket.
More reassuring is the validation. All four walk-forward folds were positive, the Probabilistic Sharpe Ratio is a near-certain 0.991, and the most recent out-of-sample fold returned 16.75% at a 1.91 Sharpe with only a 2.39% drawdown. For a mean-reversion rule, that out-of-sample consistency is the headline.
The risks
Two caveats temper the optimism. First, the returns are front-loaded in time: folds 1 and 2 (2021–2024) limped in at 4.96% and 1.91% with Sharpes of 0.37 and 0.35, while folds 3 and 4 (2024–2026) carried almost all the performance. The edge may be regime-dependent rather than durable. Second, the Deflated Sharpe Ratio of 0.563 — adjusted for 42 trials — is far more sober than the raw PSR, a reminder that some of the shine survives multiple-testing scrutiny but not all of it.
Verdict
SilentDip is a disciplined, literature-grounded strategy with genuinely clean validation and a recent out-of-sample run that inspires confidence. The open questions are whether its edge holds outside the 2024–2026 window, and whether its extreme selectivity leaves too much capital idle to matter. Worth watching — patiently, which is rather the point.